Impact of Underweight After Treatment on Prognosis of Advanced-stage Ovarian Cancer

Overview

Journal J Immunol Res

Publisher Wiley

Specialty Allergy & Immunology

Date 2014 Jul 23

PMID 25050383

Citations 20

Authors

Se Ik Kim

Hee Seung Kim

Tae Hun Kim

Dong Hoon Suh

Kidong Kim

Jae Hong No

Hyun Hoon Chung

Yong Beom Kim

Yong Sang Song

Affiliations

Soon will be listed here.

Abstract

This study aimed to investigate the impact of underweight status on the prognosis of advanced-stage ovarian cancer. A total of 360 patients with stage III-IV epithelial ovarian cancer were enrolled and divided into three groups by body mass indexes (BMIs): underweight (BMI < 18.5 kg/m(2)); normal weight to overweight (18.5 kg/m(2) BMI < 27.5 kg/m(2)); obesity (BMI ≥ 27.5 kg/m(2)). Progression-free survival (PFS), overall survival (OS), CA-125, and neutrophil to lymphocyte ratio (NLR) as a marker reflecting host inflammation and immunity were compared among the three groups according to the three treatment times: at diagnosis; after surgery; and after treatment. Only underweight status after treatment was associated with poor OS in comparison with normal weight to overweight or obesity (mean value, 44.9 versus 78.8 or 67.4 months; P = 0.05); it was also an unfavorable factor for OS (adjusted HR, 2.29; 95% CI, 1.08-4.85). Furthermore, NLR was higher in patients with underweight than in those with obesity after treatment (median value, 2.15 versus 1.47; P = 0.03), in spite of no difference in CA-125 among the three groups at the three treatment times. In conclusion, underweight status after treatment may be a poor prognostic factor in patients with advanced-stage ovarian cancer, which accompanies increased host inflammation and decreased immunity.

Citing Articles

Possible Prognostic Role of BMI Before Chemotherapy in the Outcomes of Women with Ovarian Cancer.

Paschou S, Andrikopoulou A, Mili N, Svarna A, Kaparelou M, Stefanaki K Nutrients. 2025; 17(3).

PMID: 39940415 PMC: 11820758. DOI: 10.3390/nu17030556.

Body mass index, weight change, and cancer prognosis: a meta-analysis and systematic review of 73 cohort studies.

Wen H, Deng G, Shi X, Liu Z, Lin A, Cheng Q ESMO Open. 2024; 9(3):102241.

PMID: 38442453 PMC: 10925937. DOI: 10.1016/j.esmoop.2024.102241.

Disparities in inflammation between non-Hispanic black and white individuals with lung cancer in the Greater Chicago Metropolitan area.

Byrne C, Gomez S, Kim S, Oddo V, Koh T, Fantuzzi G Front Immunol. 2022; 13:1008674.

PMID: 36544783 PMC: 9760905. DOI: 10.3389/fimmu.2022.1008674.

Is there any difference in insulin resistance status between cases of benign and malignant ovarian neoplasms? A study on surrogate markers of insulin resistance in Indonesian non-diabetic women.

Winarto H, Habiburrahman M, Febriana I, Kusuma F, Nuryanto K, Anggraeni T Oncol Lett. 2022; 25(1):23.

PMID: 36478903 PMC: 9713771. DOI: 10.3892/ol.2022.13609.

Association between Energy Balance-Related Factors and Clinical Outcomes in Patients with Ovarian Cancer: A Systematic Review and Meta-Analysis.

Stelten S, Schofield C, Hartman Y, Lopez P, Kenter G, Newton R Cancers (Basel). 2022; 14(19).

PMID: 36230490 PMC: 9559499. DOI: 10.3390/cancers14194567.

References

Morley J, Thomas D, Wilson M . Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006; 83(4):735-43. DOI: 10.1093/ajcn/83.4.735. View

Cowey S, Hardy R . The metabolic syndrome: A high-risk state for cancer?. Am J Pathol. 2006; 169(5):1505-22. PMC: 1780220. DOI: 10.2353/ajpath.2006.051090. View

Seidell J . Obesity, insulin resistance and diabetes--a worldwide epidemic. Br J Nutr. 2000; 83 Suppl 1:S5-8. DOI: 10.1017/s000711450000088x. View

Gago-Dominguez M, Castelao J, Yuan J, Ross R, Yu M . Lipid peroxidation: a novel and unifying concept of the etiology of renal cell carcinoma (United States). Cancer Causes Control. 2002; 13(3):287-93. DOI: 10.1023/a:1015044518505. View

Gilbert C, Slingerland J . Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression. Annu Rev Med. 2012; 64:45-57. DOI: 10.1146/annurev-med-121211-091527. View

Alberti K, Eckel R, Grundy S, Zimmet P, Cleeman J, Donato K . Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;.... Circulation. 2009; 120(16):1640-5. DOI: 10.1161/CIRCULATIONAHA.109.192644. View

Evans W . Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Am J Clin Nutr. 2010; 91(4):1123S-1127S. DOI: 10.3945/ajcn.2010.28608A. View

Moon H, Han W, Noh D . Underweight and breast cancer recurrence and death: a report from the Korean Breast Cancer Society. J Clin Oncol. 2009; 27(35):5899-905. DOI: 10.1200/JCO.2009.22.4436. View

Walsh S, Cook E, Goulder F, Justin T, Keeling N . Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005; 91(3):181-4. DOI: 10.1002/jso.20329. View

10.

Ho T, Gerber L, Aronson W, Terris M, Presti J, Kane C . Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database. Eur Urol. 2012; 62(5):910-6. PMC: 3500618. DOI: 10.1016/j.eururo.2012.08.015. View

11.

Kalantar-Zadeh K, Horwich T, Oreopoulos A, Kovesdy C, Younessi H, Anker S . Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care. 2007; 10(4):433-42. DOI: 10.1097/MCO.0b013e3281a30594. View

12.

Cho H, Hur H, Kim S, Kim S, Kim J, Kim Y . Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother. 2008; 58(1):15-23. PMC: 11029845. DOI: 10.1007/s00262-008-0516-3. View

13.

Renehan A, Tyson M, Egger M, Heller R, Zwahlen M . Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371(9612):569-78. DOI: 10.1016/S0140-6736(08)60269-X. View

14.

Tan B, Fearon K . Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care. 2008; 11(4):400-7. DOI: 10.1097/MCO.0b013e328300ecc1. View

15.

Kim H, Han K, Chung H, Kim J, Park N, Song Y . Neutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: a case-matched comparison. Eur J Surg Oncol. 2010; 36(7):691-8. DOI: 10.1016/j.ejso.2010.05.004. View

16.

Protani M, Nagle C, Webb P . Obesity and ovarian cancer survival: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2012; 5(7):901-10. DOI: 10.1158/1940-6207.CAPR-12-0048. View

17.

Calle E, Kaaks R . Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004; 4(8):579-91. DOI: 10.1038/nrc1408. View

18.

Evans W, Morley J, Argiles J, Bales C, Baracos V, Guttridge D . Cachexia: a new definition. Clin Nutr. 2008; 27(6):793-9. DOI: 10.1016/j.clnu.2008.06.013. View

19.

Louie S, Roberts L, Nomura D . Mechanisms linking obesity and cancer. Biochim Biophys Acta. 2013; 1831(10):1499-508. PMC: 3766377. DOI: 10.1016/j.bbalip.2013.02.008. View

20.

Tisdale M . Mechanisms of cancer cachexia. Physiol Rev. 2009; 89(2):381-410. DOI: 10.1152/physrev.00016.2008. View